期刊
MOLECULAR IMAGING AND BIOLOGY
卷 11, 期 5, 页码 343-355出版社
SPRINGER
DOI: 10.1007/s11307-009-0215-2
关键词
3 '-[F-18]fluoro-3 '-deoxythymidine; FLT; Fluorothymidine; Positron emission tomography (PET); Glioma; Radionecrosis; Proliferation imaging
资金
- National Cancer Institute [N01-CM-37008]
- NIH [CA42045, S10 RR17229]
- NATIONAL CANCER INSTITUTE [P01CA042045] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017229] Funding Source: NIH RePORTER
3'-Deoxy-3'-[F-18]fluorothymidine ([F-18]FLT) is being developed for imaging cellular proliferation. The goals were to explore the capacity of FLT-positron emission tomography (PET) to distinguish between recurrence and radionecrosis in gliomas and compare the results to those obtained with 2-fluoro-2-deoxy-d-glucose (FDG). Fifteen patients with tumor recurrence and four with radionecrosis, determined by clinical course and magnetic resonance imaging results, were studied by dynamic [F-18]FLT-PET with arterial blood sampling. A two-tissue compartment four-rate constant model was used to determine metabolic flux (K (FLT)), blood to tissue transport (K (1)), and phosphorylation (k (3)). FDG-PET scans were obtained 75-90 min postinjection. K (FLT) and k (3), but not K (1) or k (3)/k (2) + k (3), reached significance for separating the recurrence from radionecrosis groups. Standardized uptake value and visual analyses of FLT or FDG images did not reach significance. K (FLT) (flux) appears to distinguish recurrence from radionecrosis better than other parameters, FLT and FDG semiquantitative approaches, or visual analysis of images of either tracer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据